Aurisco PharmaceuticalLtd (605116) Stock Overview
Engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
605116 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Aurisco Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥26.53 |
| 52 Week High | CN¥35.58 |
| 52 Week Low | CN¥18.70 |
| Beta | 0.029 |
| 1 Month Change | -16.83% |
| 3 Month Change | 12.80% |
| 1 Year Change | 31.92% |
| 3 Year Change | 0.15% |
| 5 Year Change | 86.31% |
| Change since IPO | 120.17% |
Recent News & Updates
Recent updates
Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?
Sep 19
Is Now The Time To Put Aurisco PharmaceuticalLtd (SHSE:605116) On Your Watchlist?
Aug 14Investors Interested In Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Earnings
Jun 28Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet
Jun 07Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings
May 12Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today
Apr 22Shareholder Returns
| 605116 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.9% | -0.8% | 0.9% |
| 1Y | 31.9% | 16.1% | 28.3% |
Return vs Industry: 605116 exceeded the CN Pharmaceuticals industry which returned 18.4% over the past year.
Return vs Market: 605116 exceeded the CN Market which returned 30.5% over the past year.
Price Volatility
| 605116 volatility | |
|---|---|
| 605116 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 9.7% |
| 10% least volatile stocks in CN Market | 3.1% |
Stable Share Price: 605116 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 605116's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,784 | Dingjun Chu | www.aurisco.com |
Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs.
Aurisco Pharmaceutical Co.,Ltd. Fundamentals Summary
| 605116 fundamental statistics | |
|---|---|
| Market cap | CN¥10.78b |
| Earnings (TTM) | CN¥424.54m |
| Revenue (TTM) | CN¥1.62b |
Is 605116 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 605116 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.62b |
| Cost of Revenue | CN¥660.12m |
| Gross Profit | CN¥964.36m |
| Other Expenses | CN¥539.82m |
| Earnings | CN¥424.54m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 17, 2026
| Earnings per share (EPS) | 1.05 |
| Gross Margin | 59.36% |
| Net Profit Margin | 26.13% |
| Debt/Equity Ratio | 37.7% |
How did 605116 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 11:03 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aurisco Pharmaceutical Co.,Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Zhifeng Dai | Zhongtai Securities Co. Ltd. |
| Jiaqi Zhu | Zhongtai Securities Co. Ltd. |